Management of the coronary patient in Roberto Ferrari
|
|
- Ralph Sullivan
- 5 years ago
- Views:
Transcription
1 Management of the coronary patient in 2011 Roberto Ferrari
2 What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease?
3 Stable angina pectoris Prevalence in Europe Prevalence in community studies (Rose questionnaire) Age (yrs) Males Females % 0.1-1% % 10-15% individuals per million population (2-4%) ESC Guidelines Eur Heart J 2006
4 Stable angina pectoris Incidence in Europe Annual incidence ~0.5% in Western populations, with large geographic variations (twice as high in Scotland compared to France) ESC Guidelines Eur Heart J 2006
5 Shift in stable CAD epidemiology Decline incidence in younger Increased incidence in elderly Prevalence expected to increase
6 Despite interventional cardiology stable CAD remains a public health problem 2.6% of total health expenditure in the EU ( )
7 Pharmacological treatment of stable angina Anti-anginal (improves symptoms/exercise capacity, quality of life) Cardioprotective (prevention of cardiovascular outcomes)
8 Outcome improvement Anti-platelet agents Aspirin Clopidogrel (if aspirin not tolerated) Lipid-lowering drugs Statins ACE-inhibitors Ramipril and perindopril β-blockers Only in post MI and HF patients
9 Ivabradine Inhibits the If current of the sinus node cells Is a prototype of a new class of drugs and the first and only pure HR reducing agent
10 If current in the sinus node: the determinant of HR Sinus node Sinus node action potential and currents mv ms -50 pa I f Sinus node channels I K I CaL -50 I CaT Ca channel T- type f-channel I NaCa Ca channel L- type K channel Robinson RB, DiFrancesco D. Fundamental and Clinical Cardiology; NY; Marcel Decker; 2001:
11 Suppression of I f Current RR 0 mv Heart rate reduction exclusively -40 mv -70 mv Ivabradine 30% reduction of diastolic slope other currents maintain pacemaker activity safety factor of ivabradine
12 Ivabradine interacts internaly with the I f channel: a safety valve Closed Open Inihibited Extracellular side Intracellular side Na K Ivabradine When the channel is in closed state (bradycardia) ivabradine is inactive. Bucchi A, Baruscotti M, DiFrancesco D. J Gen Physiol. 2002;120:1-13
13 HR dependent effect of ivabradine The higher the rate, the higher the penetration, the greater the effect and vice versa Camm J et al. JACC. 2007;49 (Suppl1).Abstract.
14 Heart rate bpm HR: the determinant of ischaemia ** ** n = 19 * p<0.05 ** p< ** ** * * * ST depression Time (min) Change in HR one hour surrounding an ischaemic event Adapted from Kop WJ et al J. Am Coll C Cardiol 2001;38:
15 Ivabradine and angina Against placebo Against atenolol Against amlodipine On top of atenolol
16 Effects on HR in patients already receiving β-blockers 889 stable angina patients, 20 countries Ivabradine 5 mg bid Placebo atenolol Ivabradine atenolol (-7 bpm) 58 (-9 bpm) 56 Ivabradine 7.5 mg bid (90% of pts) or 5 mg bid (10%) 54 Tardif JC et al. Eur Heart J. 2008;29:386 Baseline M2 M4
17 Tardif JC et al. Eur Heart J. 2008;29:386. Anti-ischaemic efficacy of ivabradine in combination with -blockers patients with stable angina, 4 months of treatment ivabradine atenolol P<0.001 P<0.001 placebo atenolol P<0.001 P< Total exercise duration Time to limiting angina Time to angina onset Time to 1mm ST depression Ivabradine on top of usual dose of β-blockers improves all parameters of exercise capacity without safety concerns
18 (%) Ivabradine, contrary to β-blockers, maintains cardiac contractility Saline Ivabradine (0.5 mg/kg) Propranolol (1 mg/kg) 200 Heart rate * * * * * P <0.05 * * * ** ** -100 Baseline Rest Ex 5 Ex 10 Ex 12 (km/h) 0 * * * - 20 Baseline Rest Ex 5 Ex 10 Ex 12 (km/h) No negative inotropic effect Simon L et al. J Pharmacol Exp Ther. 275: , 1995
19 Ivabradine, contrary to β-blockers, Change from baseline (%) allows coronary dilatation 8 Simon L, et al. J Pharmacol Exp Ther. 1995;275: * Saline 0.5 mg/kg Ivabradine 1.0 mg/kg Propranolol * * p<0.05 vs. Baseline p<0.05 vs. Saline p<0.05 vs. Propranolol EXERCISE Baseline Exercise 5 min 10 min 12 min -blockade unmasking a-adrenergic vasoconstriction
20 NORADRENALINE β α Coronary dilatation Coronary constriction
21 Intrinsic more efficiency of Ivabradine vs atenolol Increase in TED related to 1 beat of heart rate reduction (after 4-month treatment) Atenolol 100 mg Ivabradine 7.5mg Ivabradine allows coronary dilatation Tardif JC, et al. Eur Heart J. 2005;26:
22 Pure HR reduction with Ivabradine does not cause the side-effects of the -blockers and calcium-channel-blockers BB CCB Ivabradine Bradycardia Hypotension Negative inotropic effect Peripheral vasoconstriction Increase coronary resistance Bronchospasm Decrease to insuline response Fatigue Depression Sleep disturbancies Erectile dysfunction Lower limbs oedema Constipation Visual effects x x x x x x x x x x x x /- x x x x x x x x
23 New EMEA indications "Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Ivabradine is indicated : in patients unable to tolerate or with a contra-indication to the use of -blockers or in combination with -blockers in patients inadequately controlled with an optimal -blocker dose and whose heart rate is > 60 bpm."
24 Ivabradine programme Symptoms release in angina ( P) Prognostic improvement in CAD with or without LV dysfunction (BEAUTifUL and SIGNifY P) Prognostic improvement in HF (SHifT P)
25 HR as a predictor of CARDIOVASCULAR DEATH HOSPITALISATION FOR HF HOSPITALISATION FOR MI REVASCULARISATION
26 Effect of ivabradine on the primary endpoint (overall population) Effect of ivabradine on the primary composite endpoint (HR 70 bpm) Effect of ivabradine on hospitalisation for MI (HR 70 bpm) Effect of ivabradine on coronary revascularisation (HR 70 bpm)
27 Event rate (%) Effect of ivabradine on primary composite end point Event rate (%) All angina patients HR >70 bpm HR (95% CI), 0.76 ( ), P= HR (95% CI), 0.69 ( ), P= Placebo 20 24% 15 Placebo 31% 10 5 Ivabradine 10 5 Ivabradine Years Years * Composite of cardiovascular mortality or hospitalization for fatal and nonfatal myocardial infarction or heart failure Fox et al. Eur Heart J. In press.
28 Event rate (%) Event rate (%) Effect of ivabradine on hospitalisation for MI All angina patients HR >70 bpm 15 HR (95% CI), 0.58 ( ), P= HR (95% CI), 0.27 ( ), P= Placebo 42% Placebo 73% 5 Ivabradine Years Ivabradine Years * Fatal and nonfatal events Fox et al. Eur Heart J. In press.
29 Treatment Placebo Angina Substudy n=773 Ivabradine Angina Substudy n=734 BEAUTifUL All n= Antithrombotics, % Statin, % Beta-blockers, % Anti-RAS, % Organic Nitrates, %
30 Ivabradine - The first anti-anginal agent with demonstrated reduction of MI in stable CAD Improved total exercise duration Improved time to onset of ST segment depression Decrease in anginal episodes Reduced Prevention revascularisation of MI Improved survival -Blockers Calcium antag. Nitrates Trimetazidine NA NA NA Ranolazine NA NA NA Nicorandil Ivabradine NA Adapted from: Guidelines on the management of stable angina pectoris. Eur Heart J. 2006;27: Fox K et al. Lancet Online August 31, 2008.
31 FROM TO
32 Why?
33 HR and the CV system HR is a determinant of the energy needs of the heart HR controls energy delivery to the heart High HR impairs endothelial function and facilitates atherosclerosis
34 HR and the heart: its cost For each beat 1.35x10-19 Ca 2 ions mobilised 300 mg ATP used for contraction 89 ml blood ejected but in a day? beats 13.5 millions of billions of Ca 2 mobilised almost 30 kg ATP immediately used 9000 lt blood ejected! km in 27 seconds!
35 HR and the heart: a reduction of 10 bpm/day saves 5 kg ATP Essential to maintain vitality
36 Coronary flow HR and the coronary arteries SYSTOLE DIASTOLE Coronary flow occurs mainly in diastole
37 HR and atherosclerosis: plaque development Diameter stenosis (%) Atherosclerotic crosssectional area (mm 2 ) Sinoatrial node ablation 136 (22) 103 (20) Heart rate Bradycardia reduces progression of atherosclerosis Beere et al. Science. 1984;226:180-2.
38 HR and atherosclerosis Custodis et al. Circ. 2008:117. HR reduction by ivabradine delays atherosclerosis in apolipoprotein E deficient mice
39 HR and coronary plaque rupture Bradycardia prevents acute coronary syndromes Heidland and Strauer. Circulation. 2001;104:
40 Ivabradine: consideration Well defined mechanism of action HR of anginal patients must be reduced to 60 bpm Ivabradine alone or on top of ß-blockers improves symptoms of angina
41 REDUCTION: Reduction of ischaemic Events by reduction of heart rate In the treatment Of stable angina with Procoralan Multicenter, prospective, open label, study (Germany); 4,954 angina pts; 4 months follow up Starting dose: 9.0 mg bid (80.3% - 5 mg bid) Average dose: 10.2 mg bid (14% mg bid) Averag e dose: 10.5 mg bid (19% mg bid) Baseline 1 month 4 months Cardiovascular therapy before Procoralan ASS 82% Statin 66% ACEI 53% ARA 19% β-blocker 54%* LA nitrates 25% CCB 25% * During the Procoralan therapy, 6.9% patients were treated concomitantly using a B-blocker. Koster R, Kaehler J, Meinertz T, for the REDUCTION Study Group. Am Heart J 2009;158:e51-e57
42 REDUCTION: proof of anti-anginal efficacy of Procoralan under routine practice conditions Multicenter, prospective, open study in angina patients in germany; 4 months follow up 3 Angina attacks 4 Acute nitrate consumption % % P< Baseline After 4 months Baseline After 4 months Efficacy was graded by physicians as being excellent/very good for 97% of the patients Koster R, Kaehler J, Meinertz T, for the REDUCTION Study Group. Am Heart J 2009;158:e51-e57 0.6
43 Study objective To assess the efficacy of ivabradine vs placebo in prevention of CV events in patients with stable CAD without clinical HF
44 Population Outpatients with stable CAD Age > 55 years With at least one other CV risk factor Without LVSD (LVEF > 40%) or clinical signs of HF
45 Population With resting HR>70 bpm (two consecutive ECG recordings at 5 min apart, at selection and inclusion visits) and in sinus rhythm Receiving appropriate guidelines driven CV medication
46 Ivabradine programme Symptoms release in angina ( P) Prognostic improvement in CAD with or without LV dysfunction (BEAUTifUL and SIGNifY P) Prognostic improvement in HF (SHifT, P)
47 Angina Rationale Angina is preceded by HR HR reduction by Ivabradine - reduces O 2 demand - improves O 2 delivery
PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationTreatment of Stable Coronary Artery Disease Pharmacotherapy
Treatment of Stable Coronary Artery Disease Pharmacotherapy José López-Sendón Hospital Universitario La Paz. Madrid. Spain Conflict of interest: I will discuss off label use and/or investigational use
More informationHeart rate lowering treatment in chronic heart failure
Heart rate lowering treatment in chronic heart failure Jaromir Hradec 3rd Dept. Med., Charles Univ., Prague Czech Republic Things we knew, things we did Things we have learnt, things we should do What
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationTrials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationSemilogarithmic relation between rest heart rate and life expectancy
The importance of heart rate in heart failure Karl Swedberg Professor of Medicine Department t of emergency and cardiovascular medicine i Sahlgrenska Academy University of Gothenburg, Sweden karl.swedberg@gu.se
More informationRANOLAZINE AND IVABRADINE - THEIR CURRENT USE
3 : 35 RANOLAZINE AND IVABRADINE - THEIR CURRENT USE Abstract Chronic stable angina is a debilitating illness affecting millions worldwide. Considerable progress has been made over the last 30 years in
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationof chronic stable angina Reshma Chunder, BPharm Elsabé van der Merwe, BPharm, MSc (Pharmacology)
Ivabradine The first I f inhibitor for the treatment of chronic stable angina Reshma Chunder, BPharm Elsabé van der Merwe, BPharm, MSc (Pharmacology) Abstract Coronary artery disease (CAD) is a highly
More informationHow to successfully manage patients with ischemic heart disease
Cardiology Update 2013 Satellite symposium A. Menarini Davos, February 14, 2013 How to successfully manage patients with ischemic heart disease François Mach Cardiology Department Geneva University Hospital
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationA Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive protein In Cardiac Patients
Human Journals Mini Review March 2017 Vol.:8, Issue: 4 All rights are reserved by Prof. Dr. Mathew George et al. A Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive
More informationManejo clínico del paciente con cardiopatía isquémica crónica y comorbilidades asociadas
Manejo clínico del paciente con cardiopatía isquémica crónica y comorbilidades asociadas José López-Sendón Hospital Universitario La Paz Madrid. Spain Starting Point What is the risk of the patient? 1-
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationCosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco. Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015
Cosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015 Treatment options for patients with chronic symptomatic
More information2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco
Modern Management of Patients with Stable Coronary Artery Disease Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco Scope of the Problem Prevalence of CAD: 17.6 million
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationPost Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationPharmacology. Drugs affecting the Cardiovascular system (Antianginal Drugs)
Lecture 7 (year3) Dr Noor Al-Hasani Pharmacology University of Baghdad College of dentistry Drugs affecting the Cardiovascular system (Antianginal Drugs) Atherosclerotic disease of the coronary arteries,
More informationCauses of death in Diabetes
Rates of CV events in Diabetes patients Respiratory4.2 Cancer 7.6 Diabetes 1.3 CV disease 17.3 Causes of death in Diabetes 250 200 150 100 50 0 per 10,000 person-years 97 151 243 Framingham 5 X increase
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationAnginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial
Angina Anginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial ischemia and pain as well as prevention of myocardial
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationStable angina: current guidelines and advances in management
DRUG REVIEW n Stable angina: current guidelines and advances in management Anoop Shah MRCP and Keith Fox FRCP Our Drug Review discusses the current recommended management of stable angina, focussing on
More informationCoronary Heart Disease. Iqbal Malik
Coronary Heart Disease Iqbal Malik Pathophysiology IHD Case chest pain Question -interactive What is the result of the exercise test? 1. negative 2. positive 3. equivocal 4. other Q2 answer STEMI! What
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationThe number of patients being treated for angina in the
Vol 4 January 2012 Clinical Pharmacist 13 Management of stable angina involves symptomatic relief of chest pain, longer-acting control of symptoms and prevention of cardiovascular complications. This article
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationÀ ². The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 September 2012
À ² The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 September 2012 PROCORALAN 5 mg film-coated tablets B/56 (CIP code: 371 676-2) B/100 (CIP code: 567 208-1) PROCORALAN
More informationAngina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room
Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University
More informationΛεωνίδας E. Πουληµένος, FESC Επιµελητής Α Ε.Σ.Υ.
Νεότερη προσέγγιση στη θεραπευτική αντιµετώπιση της Σταθερής Στηθάγχης Από τη Βέλτιστη Φαρµακευτική Αντιµετώπιση στη Βέλτιστη Θεραπευτική Προσέγγιση για τον Εκάστοτε Ασθενή: Μια καινοτόµος Προσέγγιση Λεωνίδας
More informationDRUGS USED IN ANGINA PECTORIS
DRUGS USED IN ANGINA PECTORIS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 16, 2010 Materials on: Exam #7 Required reading: Katzung, Chapter 12 1 TYPES OF ISCHEMIC HEART DISEASE
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationHeart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital
Heart Failure and COPD: Common Partners, Common Problems Nat Hawkins Liverpool Heart and Chest Hospital Disclosures: No conflicts of interest Common partners, common problems COPD in HF common partners
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationHeart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients
ESC Congress 2011 Paris 27-31 August Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients M.T. La Rovere, F. Olmetti, G.D. Pinna, R. Maestri, D. Lilleri, A. D Armini, M. Viganò,
More informationRanolazine: An Update
Ranolazine: An Update J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship Associate Professor of Medicine Brown Medical School Cardiovascular Institute Outline Ranolazine
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationΦαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας. Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.
Φαρμακευτική θεραπεία της μετεμφραγματικής καρδιακής ανεπάρκειας Α. Καραβίδας Υπεύθυνος ιατρείου καρδιακής ανεπάρκειας Γ.Ν.Α Γ.Γεννηματάς Clinical Trials on Fibrinolysis N = 61.41 AMI pts, ( GUSTO I, GUSTOIIb,
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationEffects of Ivabradine in Mitral Valve Prolapse
Original Article Effects of Ivabradine in Mitral Valve Prolapse Acta Cardiol Sin 2010;26:253 8 Electrophysiology Effects of a Novel I(f) Inhibitor; Ivabradine, on the Biochemical, Hemodynamic, and Electrophysiological
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationDrug Treatment of Ischemic Heart Disease
Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationDrug Treatment of Ischemic Heart Disease
Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE School of Medicine, The University of Jordan November, 2017 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationCase Report Potential Additive Effects of Ticagrelor, Ivabradine, and Carvedilol on Sinus Node
Case Reports in Cardiology, Article ID 932595, 4 pages http://dx.doi.org/10.1155/2014/932595 Case Report Potential Additive Effects of Ticagrelor, Ivabradine, and Carvedilol on Sinus Node Luigi Di Serafino,
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationHeart Failure A Disease for the Internist?
Heart Failure A Disease for the Internist? Dr Chris Davidson Sussex Cardiac Centre BRIGHTON UK Hot Topics in Heart Failure Drug treatments Valsartan / neprilysin inhib Investigations BNP and others Devices
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationANGINA PECTORIS. angina pectoris is a symptom of myocardial ischemia in the absence of infarction
Pharmacology Ezra Levy, Pharm.D. ANGINA PECTORIS A. Definition angina pectoris is a symptom of myocardial ischemia in the absence of infarction angina usually implies severe chest pain or discomfort during
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Third generation beta-blockers in the treatment of arterial hypertension Kurt Stoschitzky, MD, FESC Division of Cardiology Department of Internal Medicine Medical University,
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationORIGINAL ARTICLE. Edgardo Kaplinsky, Francesc Planas Comes, Ludmila San Vicente Urondo, Francesc Planas Ayma
ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 2, pp. 166 171 Copyright 2010 Via Medica ISSN 1897 5593 Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: A three month-long
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationIndependent Review Panel (IRP)
Independent Review Panel (IRP) ranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL 05 October 2012 The Scottish Medicines Consortium (SMC)
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationManaging IHD and acute Myocardial Infarction
Managing IHD and acute Myocardial Infarction In Ireland- 1 out of every 10 deaths ( 22% of all premature deaths) in 2006 were due to CVD 30,000 15,000 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 Source
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationRecommended Evaluation Data Excerpt from NVIC 04-08
Recommended Evaluation Data Excerpt from NVIC 04-08 Purpose: This document is an excerpt from the Medical and Physical Evaluations Guidelines for Merchant Mariner Credentials, contained in enclosure 3
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More information